# Corcept Therapeutics stock volatility and insider trading

> Live situation record from CLSTR: https://clstr.news/situations/corcept-therapeutics-stock-volatility-and-insider-trading
> Updated: 2026-08-20T23:23:02.000Z. Sources: 4. Developments: 2.

Corcept Therapeutics experienced a significant stock surge of approximately 228%, reaching a price of $117.17 by August 18, 2026. This growth was linked to an investment by Donald Trump, FDA support for a New Drug Application regarding relacorilant, and positive clinical trial results presented at the American Society of Clinical Oncology annual meeting.

Following the price increase, SEC filings indicated insider selling activity. On August 18, Corcept Therapeutics Director David Mahoney sold 103,606 shares at an average price of $118.25, a transaction totaling roughly $12.25 million. This sale reduced his total stake in the company by 8.37%.

By August 20, Corcept Therapeutics reported quarterly earnings of $0.36 per share, which exceeded analyst estimates.

## Timeline

### 2026-08-20: Corporate insiders execute various stock transactions

Various corporate insiders, including executives at Texas Roadhouse and Corcept Therapeutics, have executed significant stock sales and purchases according to recent SEC filings.

2 sources. https://clstr.news/cluster/flex-and-corcept-therapeutics-report-insider-stock-sales

### 2026-08-18: Corcept Therapeutics stock surges 228% following Trump investment

Donald Trump’s investment in Corcept Therapeutics has grown approximately 228% since March, driven by FDA developments, positive clinical trial results, and news regarding generic drug tariffs.

2 sources. https://clstr.news/cluster/corcept-therapeutics-stock-surges-228-following-trump-investment

---
Cite as: Corcept Therapeutics stock volatility and insider trading. CLSTR, https://clstr.news/situations/corcept-therapeutics-stock-volatility-and-insider-trading